Neovascular Disease
Community Case in nAMD
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Retinal Disease Digest on nAMD: Opportunities for Optometrists
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc., and Ocular Therapeutix, Inc.
Clinical Trial Updates in nAMD, DME, RVO, MacTel, and GA Management
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; Neurotech Pharmaceuticals, Inc.; Astellas; EyePoint Pharmaceuticals, Inc.; Opthea Ltd.; Topcon Healthcare, Inc.; Outlook Therapeutics; REGENXBIO Inc.; Ocuphire Pharma; and Carl Zeiss Meditec, Inc.
Taming the Tide: Management of Persistent Retinal Fluid in nAMD and DME
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
nAMD and DME Management: Game-Changing Sustained Delivery Platforms
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C & D
This activity is supported by an educational grant from Opthea.
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
This activity is supported by Regeneron Pharmaceuticals, Inc.
Extending Dosing Intervals in Retinal Disease: Patient Perspectives and Clinical Insights to Guide Your Practice
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
nAMD and DME: Novel Treatment Plans to Prioritize Real-World Visual Improvements
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Personalized Approaches for Treating nAMD and DME
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.